Furthermore, we observed high expression levels of the genes encoding LAG3 and TIM3 in the ovarian tumor tissue in both our cohort and the cohort from Kreuzinger et al., and indeed LAG3 and HAVCR2 (TIM3) were also expressed to a higher degree than PD1 on the in vitro expanded CD8+TILs from the recurrent tumor, indicating these checkpoint components play an inhibitory role in the TME of ovarian cancer and suggesting they may be attractive targets for new immunotherapies. The gene discussed is CD8A; the disease is ovarian cancer.